Navigation Links
Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Date:9/3/2008

TUSTIN, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2009 on September 9, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2008 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m. PDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through September 16, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead pro
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...tion of ultrasmall transistors and more powerful c...ducting nanowires are closer to reality after a ke...ty and the University of California at Los Angeles...anowires with layers of different materials that a... critical requirement for making efficient transis...
(Date:11/25/2009)...A RATON, Fla., Nov. 25 For many bu... BodyLogicMD. The nation,s largest and fastest gr...clusively in medically supervised bioidentical ho...its network since November 2008 - from 21 to 36...ician-owned centers, including one in Puerto Rico,...
(Date:11/25/2009)...re-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: ....D., president and chief executive officer, will p...e Conference. , ,Presentation details are as foll...ence,Date: Tuesday, December 1, 2009,Time: ...Palace Hotel, New York, NY,Webcast: <a href=,ht...
(Date:11/24/2009)...vestment bank KTA Capital,s client Neuren Pharmace...vertible note private placement with a U.S. instit...ed by KTA Capital as Neuren,s exclusive placement ...York (PRWEB) November 23, 2009 -- The independent ...TA Capital") has announced that its client Ne...
Breaking Biology Technology:Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...nt Portfolio -, SAN DIEGO, Oct. 2 Orexigen(R) Th...cal company focused on the treatment,of obesity an...today,announced the initiation of its first clinic...lease formulation of zonisamide plus olanzapine.,T... examine the,effectiveness of OREX-003 in mitigati...
...,(Nasdaq: CLRT ), a premier anatomic pathology an...ists, oncologists and the pharmaceutical industry,...rews, is featured in an,exclusive interview on Wal...es viewers an overview of the company, and the,sig... To view the clip in its entirety, visit:, http:...
...otherapy in U.S. to be Indicated ... Cell Therapeutics, Inc. (CTI),(Nasdaq and MTA: C...emental,Biologics License Application (sBLA) with ...e of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,co...reviously untreated,patients with follicular non-H...
Other Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:11/26/2009)...European countries has shown that closing schools ...ld have a significant role in reducing illness tra...journal BMC Infectious Diseases compared opportu...olidays, finding that they were reduced when schoo...rp University, Belgium, led a team of European res...
(Date:11/25/2009)... the stomach, may be used to boost resistance to, ...ale School of Medicine researchers report in a stu...Neuroscience . , Parkinson,s disease is caused b... the midbrain known as the substantia nigra, which...production of dopamine in late-stage Parkinson,s c...
(Date:11/25/2009)... the heart pumps some 250 million liters of blood ...cle fibers of the heart have to be extremely durab...bauer, vice chair of the Department of Medicine II...f. Dr. H. A. Katus), has discovered a protein that...muscular unit, the sarcomere. In cooperation with ...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Dallas County Jury Finds in Favor of Family in Medical Malpractice Suit 61260 1Dallas County Jury Finds in Favor of Family in Medical Malpractice Suit 61260 2GREENGUARD Launches Comprehensive Health Based Certification Pilot Program 61257 1GREENGUARD Launches Comprehensive Health Based Certification Pilot Program 61257 2First Citizens Bank to Offer mPay Gateways Point of Care Patient Payment System to Its Health Care Customers 61254 1First Citizens Bank to Offer mPay Gateways Point of Care Patient Payment System to Its Health Care Customers 61254 2
...NTO, ON Researchers are closer to understanding w...e way they look, behave, think, and fight off dise...tical. , Innovative research from the Universi...r Research has uncovered potential new explanation...n and heart tissue from humans and chimpanzees, U ...
...orld leaders prepare to discuss conservation-frien...ve threatens a new wave of deforestation in the So...sity of East Anglia and Brazils Goeldi Museum high...primary rain forest. , Working in the north-east...entists undertook the single-largest assessment of...
...anxiety and aggression that result from social iso...zyme that controls production of a brain hormone. ...niversity of Illinois at Chicago College of Medici...the Proceedings of the National Academy of Science...because social isolation in both animals and human...
Other Biology News:University of Toronto finds humans and chimps differ at level of gene splicing 2Single-largest biodiversity survey says primary rainforest is irreplaceable 2Effects of social isolation traced to brain hormone 2
Amino Acid Mixture Minus Leucine from Promega
Zero Blunt TOPO PCR Cloning Kit for Sequencing with One Shot TOP10 Electrocomp E. coli from Invitrogen
Zero Blunt TOPO PCR Cloning Kit for Sequencing with One Shot TOP10 Electrocomp E. coli from Invitrogen
Cultrex BME with phenol red from Trevigen
Biology Products: